Study guide

6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689)

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689)

Key Takeaways Explain This Topic AI

ORS 689.689 lets Oregon pharmacists prescribe and administer injectable contraception (DMPA) and prescribe and dispense pills, patches and rings after Board-approved training.

Under the Oregon contraception protocol, the patient completes an intake form at least every 12 months, and US MEC 2024 Category 3 or 4 findings require referral.

An Oregon pharmacist may accept a self-reported or measured blood pressure. Combined methods need BP under 140/90 and DMPA under 160/100.

Oregon pharmacists may prescribe up to 12 months of contraception, may not require an appointment and must refer if there was no women's health visit within 3 years after the first pharmacist prescription.

Neither ORS 689.689 nor the current Oregon protocol sets a minimum age or requires minors to show a prior prescription.

Last updated: October 2026

Why this matters

Oregon was the first state to let pharmacists prescribe hormonal contraception (2015, now ORS 689.689). The law has changed since then. Old study materials describe a requirement that minors show a prior prescription and a ban on self-reported blood pressure. Neither is part of the current statute or Board protocol (v. 06/2025). This section teaches the current rules.

Statutory authority (ORS 689.689)

A pharmacist may prescribe and administer injectable hormonal contraceptives and prescribe and dispense self-administered hormonal contraceptives , following Board rules developed with the Oregon Medical Board, the Nursing Board and OHA and in light of ACOG guidance. The rules must require the pharmacist to:

Complete a Board-approved training program . The protocol specifies a Board-approved, ACPE-accredited program.

Provide a self-screening risk assessment tool that the patient completes before prescribing.

Refer the patient to a primary care or women's health care practitioner upon prescribing.

Give the patient a written record of the contraceptive and advise consulting a primary care or women's health practitioner.

Dispense or administer as soon as practicable after issuing the prescription.

The rules must prohibit the pharmacist from:

Requiring an appointment (an appointment may be offered, not required; OAR 855-115-0335).

Prescribing to a patient who has no evidence of a clinical visit for women's health within the three years immediately following the pharmacist's initial contraceptive prescription.

Insurance laws on contraceptive coverage apply to pharmacist-prescribed contraceptives (ORS 689.689(3)). Under ORS 743A.066, prescription benefit programs must reimburse a 3-month supply at the first dispensing and a 12-month supply for subsequent dispensings of the same contraceptive.

Methods covered

The protocol covers oral contraceptives (combined and progestin-only), the transdermal patch , the vaginal ring and injectable depot medroxyprogesterone acetate (DMPA) , IM or SQ. A pharmacist may administer DMPA. Long-acting reversible methods, such as IUDs and implants, are not covered and require referral.

The protocol care pathway (v. 06/2025)

Step Requirement

1. Intake form The patient completes the Board's Contraception Self-Screening Patient Intake Form, renewed at least every 12 months

2. Exclusion check Refer if the patient was previously prescribed contraception by a pharmacist and has had no non-pharmacist reproductive or sexual health visit within the 3 years after that first pharmacist prescription

3. Pregnancy screen If pregnancy cannot reasonably be ruled out, refer

4. Medical and medication history Apply the 2024 U.S. Medical Eligibility Criteria (US MEC) . Any Category 3 or 4 condition or significant interaction for the chosen method means refer (or choose another method that is Category 1–2)

5. Blood pressure The pharmacist may accept a self-reported BP or measure it . Combined hormonal contraception requires BP under 140/90 . DMPA requires BP under 160/100 . If above the limit, refer or consider a progestin-only option

6. Prescribe Up to 12 months of the selected product, dispensed as soon as practicable

7. Counsel Side effects, starting strategy (quick start with 7 days of backup unless within 5 days of the last menstrual period), adherence, STI prevention, and follow-up (DMPA IM every 11–13 weeks)

8. Visit summary Give the patient the visit summary, advise a primary care or women's health visit, and notify the provider (within 5 business days under OAR 855-115-0330)

No minimum age appears in ORS 689.689 or the current protocol. A minor's eligibility follows the same screening pathway.

High-yield US MEC examples

  • Condition Combined (estrogen) methods Progestin-only pill / DMPA
  • Migraine with aura Category 4: refer or use another method Category 1–2
  • Age 35 or older and smoking 15+ cigarettes/day Category 4 Category 1
  • BP at or above 160/100 Category 4 DMPA Category 3 (refer); POP Category 2
  • Current breast cancer Category 4 Category 4
  • History of DVT/PE, not on anticoagulation Category 3 (lower recurrence risk) or 4 (higher risk) Category 2

The pharmacist must consult the full 2024 US MEC tables (Appendices C and D) for the specific method. The summary chart is a screening aid, not a substitute.

Emergency contraception and condoms

Separate protocols cover emergency contraception and condoms . Levonorgestrel 1.5 mg is also available without a prescription under federal law. A protocol prescription lets the product be billed and documented as a prescription.

Exam scenario

A 17-year-old asks for a combined oral contraceptive. She has never had hormonal contraception and has no women's health visit history. She completes the intake form. Her answers rule out pregnancy and show no US MEC Category 3–4 conditions, and her self-reported BP is 118/76. Under the current statute and protocol, there is no age bar and no prior-prescription requirement , so the pharmacist may prescribe up to a 12-month supply. The pharmacist counsels on backup for 7 days, gives a visit summary, advises a primary care or women's health visit, and notifies any identified provider within five business days. The 3-year clinical-visit rule will matter only if she returns to a pharmacist for contraception later.